Adrian Thomas Gonon

Adrian Thomas Gonon

Auto-generated profile, based on publicly available information

Adrian Thomas Gonon

Department of Clinical Science, Intervention & Technology, Karolinska Institutet, Stockholm, Sweden

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 August 2013 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
JYJiangning Yang
Jiangning Yang
AGAdrian T. Gonon
Adrian T. Gonon
PSPer-Ove Sjöquist
Per-Ove Sjöquist
JLJon O. Lundberg
Jon O. Lundberg
JPJohn Pernow
John Pernow
The theory that red blood cells (RBCs) generate and release nitric oxide (NO)-like bioactivity has gained considerable interest. However, it remains unclear whether it can be produced by endothelial NO synthase (eNOS), which is present in RBCs, and whether NO can escape scavenging by hemoglobin. The aim of this study was to test the hypothesis that arginase reciprocally controls NO formation in RBCs by competition with eNOS for their common substrate arginine and that RBC-derived NO is functionally active following arginase blockade. We show that rodent and human RBCs contain functional arginase 1 and that pharmacological inhibition of arginase increases export of eNOS-derived nitrogen oxides from RBCs under basal conditions. The functional importance was tested in an ex vivo model of myocardial ischemia-reperfusion injury. Inhibitors of arginase significantly improved postischemic functional recovery in rat hearts if administered in whole blood or with RBCs in plasma. By contrast, arginase inhibition did not improve postischemic recovery when administered with buffer solution or plasma alone. The protective effect of arginase inhibition was lost in the presence of a NOS inhibitor. Moreover, hearts from eNOS−/− mice were protected when the arginase inhibitor was given with blood from wild-type donors. In contrast, when hearts from wild-type mice were given blood from eNOS−/− mice, the arginase inhibitor failed to protect against ischemia-reperfusion. These results strongly support the notion that RBCs contain functional eNOS and release NO-like bioactivity. This process is under tight control by arginase 1 and is of functional importance during ischemia-reperfusion.

2 September 2009 in Cardiovascular Research
Verified
Journal Article
Open access
PDF file
CJChristian Jung
Christian Jung
AGAdrian T. Gonon
Adrian T. Gonon
PSPer-Ove Sjöquist
Per-Ove Sjöquist
JLJon O. Lundberg
Jon O. Lundberg
JPJohn Pernow
John Pernow
Nitric oxide (NO) is vital for the integrity of the cardiovascular system and protection against ischaemic heart disease. Arginase is up-regulated during ischaemia–reperfusion (IR) and this enzyme might compete with NO synthase (NOS) for arginine. The present study investigated whether arginase blockade protects from myocardial IR injury and whether such an effect is coupled to increased NO bioavailability. Sprague–Dawley rats were subjected to 30 min of coronary artery ligation, followed by 2 h of reperfusion. The animals were given either saline, or the arginase inhibitor N-omega-hydroxy-nor-l-arginine (nor-NOHA) with or without the NO scavenger carboxy-2-phenyl-4,4,5,5-tetramethyl-imidazoline-1-oxyl-3-oxide (cPTIO) or the NOS inhibitor NG-monomethyl-l-arginine (l-NMMA) iv 15 min before ischaemia. The infarct size was 79 ± 4% of the area at risk in the control group. Nor-NOHA treatment reduced the infarct size to 39 ± 7% (P < 0.001). Administration of cPTIO or l-NMMA completely abolished the protective effect of nor-NOHA. Expression of arginase I was significantly (P < 0.05) increased in ischaemic myocardium. Nor-NOHA treatment resulted in higher plasma levels of nitrite (P < 0.05) and a 10-fold increase in the citrulline/ornithine ratio (P < 0.001), indicating a shift in arginine utilization towards NOS. Inhibition of arginase protects from myocardial infarction by a mechanism that is dependent on NOS activity and bioavailability of NO by shifting arginine utilization from arginase towards NOS. These findings suggest that targeting of arginase is a promising future therapeutic strategy for protection against myocardial IR injury.

25 January 2008 in Cardiovascular Research
Verified
Journal Article
Open access
PDF file
AGAdrian T. Gonon
Adrian T. Gonon
UWUlrika Widegren
Ulrika Widegren
ABAliaksandr Bulhak
Aliaksandr Bulhak
FSFiroozeh Salehzadeh
Firoozeh Salehzadeh
JPJonas Persson
Jonas Persson
JPJohn Pernow
John Pernow
Cardiovascular disease and type 2 diabetes mellitus are associated with low plasma concentration of adiponectin. The aim of this study was to investigate whether adiponectin exerts cardioprotective effects during myocardial ischaemia-reperfusion and whether this effect is related to the production of nitric oxide (NO). Isolated rat hearts were subjected to 30 min of either global or local ischaemia followed by 60 min of reperfusion. The hearts received vehicle, adiponectin (3 µg/mL), the NO-synthase inhibitor nitro-l-arginine (l-NNA) (0.1 mM), or a combination of adiponectin and l-NNA at the onset of ischaemia. Haemodynamics, infarct size, and expression of endothelial NO-synthase (eNOS), AMP-activated protein kinase (AMPK), and Akt were determined. Adiponectin significantly increased left ventricular function and coronary flow during reperfusion in comparison with the vehicle group. Co-administration of l-NNA abrogated the improvement in myocardial function induced by adiponectin. Infarct size following local ischaemia-reperfusion was 40 ± 6% of the area at risk in the vehicle group. Adiponectin reduced infarct size to 19 ± 2% (P < 0.01). l-NNA did not affect infarct size per se but abolished the protective effect of adiponectin (infarct size 40 ± 5%). Phosphorylation of eNOS Ser1177, AMPK Thr172, and Akt Ser 473 was increased in the adiponectin group (P < 0.05). Adiponectin protects from myocardial contractile dysfunction and limits infarct size following ischaemia and reperfusion by a mechanism involving activation of AMPK and production of NO.

27 December 2011 in Diabetologia
Verified
Journal Article
Closed access
ARA. Rafnsson
A. Rafnsson
FBF. Böhm
F. Böhm
MSM. Settergren
M. Settergren
AGA. Gonon
A. Gonon
KBKerstin Brismar
Kerstin Brismar
JPJohn Pernow
John Pernow

31 July 2012 in PLOS ONE
Verified
Journal Article
Open access
PDF file
AGAdrian T. Gonon
Adrian T. Gonon
CJChristian Jung
Christian Jung
AKAbram Katz
Abram Katz
Håkan WesterbladHåkan Westerblad
Håkan Westerblad
ASAlexey Shemyakin
Alexey Shemyakin
JPJohn Pernow
John Pernow
Consumption of L-arginine contributes to reduced bioavailability of nitric oxide (NO) that is critical for the development of ischemia-reperfusion injury. The aim of the study was to determine myocardial arginase expression and activity in ischemic-reperfusion myocardium and whether local inhibition of arginase within the ischemic myocardium results in increased NO production and protection against myocardial ischemia-reperfusion. Anesthetized pigs were subjected to coronary artery occlusion for 40 min followed by 4 h reperfusion. The pigs were randomized to intracoronary infusion of vehicle (n = 7), the arginase inhibitor N-hydroxy-nor-L-arginine (nor-NOHA, 2 mg/min, n = 7), the combination of nor-NOHA and the NO synthase inhibitor NG-monomethyl-L-arginine (L-NMMA, 0.35 mg/min, n = 6) into the jeopardized myocardial area or systemic intravenous infusion of nor-NOHA (2 mg/min, n = 5) at the end of ischemia and start of reperfusion. The infarct size of the vehicle group was 80±4% of the area at risk. Intracoronary nor-NOHA reduced infarct size to 46±5% (P<0.01). Co-administration of L-NMMA abrogated the cardioprotective effect mediated by nor-NOHA (infarct size 72±6%). Intravenous nor-NOHA did not reduce infarct size. Arginase I and II were expressed in cardiomyocytes, endothelial, smooth muscle and poylmorphonuclear cells. There was no difference in cytosolic arginase I or mitochondrial arginase II expression between ischemic-reperfused and non-ischemic myocardium. Arginase activity increased 2-fold in the ischemic-reperfused myocardium in comparison with non-ischemic myocardium. In conclusion, ischemia-reperfusion increases arginase activity without affecting cytosolic arginase I or mitochondrial arginase II expression. Local arginase inhibition during early reperfusion reduces infarct size via a mechanism that is dependent on increased bioavailability of NO.

1 July 2013 in European Journal of Pharmacology
Verified
Journal Article
Closed access
YTYahor Tratsiakovich
Yahor Tratsiakovich
AGAdrian Thomas Gonon
Adrian Thomas Gonon
AKAnna Krook
Anna Krook
JYJiangning Yang
Jiangning Yang
ASAlexey Shemyakin
Alexey Shemyakin
JPJohn Pernow
John Pernow